Abstract
The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months. The selection of an effective first-line treatment represents a crucial point in order to achieve good outcome results. In the last years, the intensive FOLFOXIRI regimen in combination with bevacizumab became a new standard option in this setting. In the present review we summarized the main steps of FOLFOXIRI regimen development from the first pilot study to the recent findings with biological agents, with a specific focus on practical aspects, such as patient's selection, adverse event management, treatment schedules and post-progression strategies. Possible predictive markers, open issues and ongoing clinical trials have been also deeply described.
Keywords:
Anti-EGFR; Bevacizumab; FOLFOXIRI; First-line; Metastatic colorectal cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab / administration & dosage
-
Bevacizumab / adverse effects
-
Biomarkers, Tumor / analysis
-
Camptothecin / adverse effects
-
Camptothecin / analogs & derivatives*
-
Camptothecin / therapeutic use
-
Colorectal Neoplasms / diagnosis
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology*
-
Dose-Response Relationship, Drug
-
Fluorouracil / adverse effects
-
Fluorouracil / therapeutic use
-
Humans
-
Leucovorin / adverse effects
-
Leucovorin / therapeutic use
-
Maintenance Chemotherapy
-
Neoadjuvant Therapy / methods
-
Neoplasm Metastasis
-
Organoplatinum Compounds / adverse effects
-
Organoplatinum Compounds / therapeutic use
Substances
-
Biomarkers, Tumor
-
Organoplatinum Compounds
-
Bevacizumab
-
Leucovorin
-
Fluorouracil
-
Camptothecin